Evidence map›Paper›PMID 42540286›Full record

ArticleCureus2026

Bioequivalence of Fixed-Dose Dapagliflozin-Pioglitazone in Healthy Indian Adults: Results From the Randomized Crossover PRO-4 Study.

J Hari Prasath, Umesh Garg, Kalyan Kurapati, Abhamoni Baro Agarwal, Parul Singhal, Thamburaj Anthuvan, Smriti Gadia, Amit Gupta, Sridhar S B

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

J Hari PrasathInternal Medicine, Apollo First Med Hospitals, Chennai, IND.
Umesh GargEndocrinology and Diabetes, Pushpanjali Hospital and Research Centre, Agra, IND.
Kalyan KurapatiCardiology, Shalini Heart Hospital, Nizamabad, IND.
Abhamoni Baro AgarwalEndocrinology, Arya Wellness Centre, Guwahati, IND.
Parul SinghalEndocrinology and Diabetes, Singhal Clinic, Kashipur, IND.
Thamburaj AnthuvanSales and Marketing, USV Private Limited, Mumbai, IND.
Smriti GadiaScientific Services, USV Private Limited, Mumbai, IND.
Amit GuptaScientific Services, USV Private Limited, Mumbai, IND.
Sridhar S BClinical Research, USV Private Limited, Mumbai, IND.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective The study assessed the bioequivalence of a fixed-dose combination (FDC) of dapagliflozin 10 mg/pioglitazone 15 mg co-administered with the reference products Forxiga® 10 mg: AstraZeneca Pharmaceuticals LP, Indiana, USA and Pioglit® 15 mg: Sun Pharma Laboratories Ltd., Assam, India in healthy adult participants under fasting conditions. Materials and methods A randomized, open-label, single-dose, two-period, crossover design was used in the study. Eligible participants were randomly assigned to receive either the test FDC or the respective reference products during the first period, followed by the administration of the alternate treatment after a 7-day washout interval. The primary pharmacokinetic parameters included maximum plasma concentration (C

Indexed as

bioequivalencecrossover studydapagliflozinfixed-dose combinationpioglitazone

Identifiers

PMID42540286
PMCPMC13425340

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.